Close Menu

This article has been updated to correct that PacBio's instrument sales, not Sequel II sales, were up year over year in Q3.

NEW YORK – Oxford Nanopore Technologies told UK regulators last week that it believes Illumina's offer to license sequencing-related intellectual property to third parties in order to gain approval for its proposed acquisition of Pacific Biosciences doesn't go far enough.

Instead, ONT suggested Illumina divest its NovaSeq platform, arguably the company's most successful product line at the moment.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.

Sponsored by

This webinar features two speakers who will discuss novel computational approaches to optimize sequencing workflows on Oxford Nanopore sequencing platforms.

Sponsored by

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.